Skip to main content
Industry News
FDA OKs injectable fosphenytoin for status epilepticus

Sedor Pharmaceuticals' Sesquient, or fosphenytoin sodium injection, gained the FDA's nod as a treatment for pediatric and adult status epilepticus. The formulation is room-temperature stable and ready to dilute, and it is indicated for the treatment and prevention of seizures in adults that occur during neurosurgery and as a short-term substitute for oral phenytoin in pediatric patients ages 2 years and older.

Full Story: